Cancer Clinical Trials for Adolescents and Young Adults

UnityPoint Clinic Urgent Care - Altoona

00 Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

01 Patients
Waiting Now

Urgent Care - Ankeny

01 Patients
Waiting Now

Urgent Care - Lakeview

03 Patients
Waiting Now

Urgent Care - Merle Hay

05 Patients
Waiting Now

Urgent Care - Southglen

06 Patients
Waiting Now

Urgent Care - Urbandale

00 Patients
Waiting Now
Blank Children's Hospital

AYA Clinical Trials

General

APEC14B1: The Project:EveryChild Protocol: A Registry, Eligibility, Screening, Biology, and Outcome Study
Age: 25 years or younger

CNS

ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma 
Age: 1-21 years

ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Age: Younger than 22 years

Leukemia

AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia. 
Age: Younger than 21 years

AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia 
Age: Younger than 22 years

AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones 
Age: Younger than 22 years

Lymphoma

AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Age: Younger than 22 years

Germ Cell

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Low Risk Age: Younger than 50 years; Standard Risk Age: Younger than 25 years

AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors. 
Age: Younger than 46 years

Hepatoblastoma

AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial 
Age: Younger than 31 years

Sarcoma

ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide Alternating with Vincristine and Irinotecan Versus VAC/VI Plus Temsirolimus in Patients with Intermed. Risk Rhabdomyosarcoma
Age: Younger than 21 years

Refractory Solid Tumors

ADVL1622: Plase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule SMall-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors.
Age: Younger than 31 years

Late Effects

ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial 
Age: Less than 22 years; more than 2 years post-tx

Match Trial - Younger than 22 years

APEC1621 SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

APEC1621 A: Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions

APEC1621 B: Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations

APEC1621 D: Phase 2 subprotocol of LY3023414 in Solid Tumors

APEC1621 E: Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations.

APEC1621 F: Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

APEC1621 G: Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

APEC1621 H: Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

APEC1621 I: Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

APEC1621 J: Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations